secwatch.observer — SEC 8-K summary
======================================

Issuer:     NextCure, Inc. (NXTC)
CIK:        0001661059
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0001558370-24-010598
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NextCure reports Q2 net loss $15.4M; cash $86.4M; LNCB74 IND on track for year-end
--------------------------------------------------------------------------------

- Net loss $15.4M in Q2 2024 vs $17.9M in Q2 2023; R&D expenses $12.4M (down from $13.4M).
- Cash & marketable securities $86.4M as of June 30, 2024; expected to fund operations into H2 2026.
- LNCB74 (B7-H4 ADC) GLP tox studies completed; IND submission planned by year-end 2024.
- NC410 + pembrolizumab ovarian cohort enrollment completed (16 additional patients); data expected Q4 2024.
- NC181 (Alzheimer's) manufacturing initiated for tox studies; seeking partnering/funding for IND mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661059/000155837024010598/0001558370-24-010598-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661059/000155837024010598/nxtc-20240801x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-010598

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer